Shareholder AnnouncementDear Shareholder,I am pleased to announce that we have entered into an Agreement with MSD (or Merck Sharp & Dohme, tradename of Merck & Co., USA), to evaluate our lead anticancer pharmaceutical tigilanol tiglate in combination with MSD’s Keytruda® (pembrolizumab) in patients with melanoma. The Agreement encompasses a clinical trial collaboration to investigate the safety and preliminary efficacy of tigilanol tiglate when administered in combination with Keytruda® in a Phase Ib/IIa open label, dose escalation study. What we hope to see through this program, is that when combined, tigilanol tiglate and Keytruda® will be safe and produce an additive anti-tumour immune response with an improved outcome for patients. This clinical collaboration is a significant milestone for QBiotics, and we are delighted to work with such a high calibre company as MSD on this study. Melanoma is the second human application QBiotics is pursuing for tigilanol tiglate following on from our Phase Ib/IIa clinical trial in patients with Head and Neck Squamous Cell Carcinoma which commenced in December 2019.
- Forums
- ASX - General
- cure for cancer...you can invest
cure for cancer...you can invest, page-324
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)